Schubert & Co’s PTC Therapeutics PTCT Stock Holding History

Schubert & Co’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-9	Closed	-$436	–	1154
2023 Q1	$436	Buy	9 +2	+29%	+$91	﹤0.01%	1445
2022 Q4	$267	Buy	7 +3	+75%	+$125	﹤0.01%	1496
2022 Q3	$0	Buy	+4	New	+$196	﹤0.01%	1532

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Schubert & Co's PTCT Position: Q2 2023 in Review

Schubert & Co sold out of PTC Therapeutics (PTCT) in Q2 2023, closing a stake of 9 shares — an estimated $436 sold.

Schubert & Co first reported a position in PTCT in Q3 2022 and held it in 3 quarters. The position peaked at $436 in Q1 2023. 204 funds tracked by Wall St. Rank hold PTCT as of Q2 2023.

Schubert & Co reported no remaining PTC Therapeutics position as of Q2 2023 after selling out during the quarter.
Schubert & Co sold 9 PTC Therapeutics shares in Q2 2023, an estimated $436.
Schubert & Co first reported a position in PTC Therapeutics in Q3 2022 and held it in 3 quarters.
Schubert & Co's PTC Therapeutics position peaked at $436 in Q1 2023.
204 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.